Oncogenic mutant forms of EGFR: lessons in signal transduction and targets for cancer therapy.
about
EGCG, green tea polyphenols and their synthetic analogs and prodrugs for human cancer prevention and treatmentLigand-Independent EGFR SignalingToward a magic or imaginary bullet? Ligands for drug targeting to cancer cells: principles, hopes, and challengesUnderstanding the Impact of ErbB Activating Events and Signal Transduction on Antigen Processing and Presentation: MHC Expression as a Model.A potential peptide therapeutic derived from the juxtamembrane domain of the epidermal growth factor receptorSpatially defined EGF receptor activation reveals an F-actin-dependent phospho-Erk signaling complex.Suppressor of Cytokine Signaling (SOCS) 5 utilises distinct domains for regulation of JAK1 and interaction with the adaptor protein Shc-1.Epidermal Growth Factor Receptor Cell Proliferation Signaling PathwaysCell surface epidermal growth factor receptors increase Src and c-Cbl activity and receptor ubiquitylation.miR-126&126* restored expressions play a tumor suppressor role by directly regulating ADAM9 and MMP7 in melanoma.Targeting mTOR to overcome epidermal growth factor receptor tyrosine kinase inhibitor resistance in non-small cell lung cancer cellsPim1 kinase is upregulated in glioblastoma multiforme and mediates tumor cell survival.Identification of an exon 4-deletion variant of epidermal growth factor receptor with increased metastasis-promoting capacity.Extracellular ATP stimulates epithelial cell motility through Pyk2-mediated activation of the EGF receptorCombined treatment of Nimotuzumab and rapamycin is effective against temozolomide-resistant human gliomas regardless of the EGFR mutation status.EGF receptor deletion in podocytes attenuates diabetic nephropathy.Cooperative Hedgehog-EGFR signalingConstitutive asymmetric dimerization drives oncogenic activation of epidermal growth factor receptor carboxyl-terminal deletion mutants.Lung cancer-derived galectin-1 enhances tumorigenic potentiation of tumor-associated dendritic cells by expressing heparin-binding EGF-like growth factor.Kinase Inhibitor Profiling Reveals Unexpected Opportunities to Inhibit Disease-Associated Mutant Kinases.Inhibition of DHHC20-Mediated EGFR Palmitoylation Creates a Dependence on EGFR Signaling.Specific inhibition of tumor cells by oncogenic EGFR specific silencing by RNA interference.CTEN prolongs signaling by EGFR through reducing its ligand-induced degradationEpidermal growth factor receptor (EGFR) signaling regulates epiphyseal cartilage development through β-catenin-dependent and -independent pathways.Inactive ERBB receptors cooperate with reactive oxygen species to suppress cancer progression.Oncogene-Selective Sensitivity to Synchronous Cell Death following Modulation of the Amino Acid Nutrient Cystine.PET tracers based on Zirconium-89.The regulatory role of the juxtamembrane region in the activity of the epidermal growth factor receptor.Endocytosis and signaling: cell logistics shape the eukaryotic cell plan.EGFR-dependent mechanisms in glioblastoma: towards a better therapeutic strategy.New horizons in therapeutic antibody discovery: opportunities and challenges versus small-molecule therapeutics.Molecular dynamics simulations of transitions for ECD epidermal growth factor receptors show key differences between human and drosophila forms of the receptors.Approaches to identify kinase dependencies in cancer signalling networks.Vertical suppression of the EGFR pathway prevents onset of resistance in colorectal cancers.Posttranslational modifications of FOXO1 regulate epidermal growth factor receptor tyrosine kinase inhibitor resistance for non-small cell lung cancer cells.A comparative study of affibody, panitumumab, and EGF for near-infrared fluorescence imaging of EGFR- and EGFRvIII-expressing tumors.Tumor-associated macrophages regulate murine breast cancer stem cells through a novel paracrine EGFR/Stat3/Sox-2 signaling pathway.Annexin A6 is a scaffold for PKCα to promote EGFR inactivation.Phosphoproteomic studies of receptor tyrosine kinases: future perspectives.p53 modulates acquired resistance to EGFR inhibitors and radiation.
P2860
Q24616455-0ACB33FF-CE43-43EF-9618-A3E436BF5DA9Q26797495-0087F5A7-E758-45BB-B930-85DC1A7C9F6CQ26995399-48763BE7-6AA4-4E29-AE8E-2E68A3E41962Q27691330-7BE6CD1E-0894-45DB-B80C-53F0744ED9A2Q28485213-773B6794-3E6B-417D-9052-74888D37C12DQ30362141-A6DE2DE7-0944-4335-8A32-20A99EA1D7F8Q31130829-8B0F1DD2-117D-4C1C-9C4E-9B2F9CCB426DQ33737298-1BA2D49B-1A19-4C23-ABDE-0C2E9FDEF094Q34170653-FAF66B70-9746-470C-83FE-1C29196A9E15Q34599550-A8880086-D2DA-4E27-A125-409DCFC917C2Q34852951-D5B8C2A6-FC68-4567-B5D4-14FEC47E7528Q34886884-E9F0CE6D-83C5-4287-87DC-572EC568CC0BQ34887667-4A430528-E00E-4AD8-8B8C-98660C0FF0BEQ35250443-1D891FED-33CE-4306-9EFD-7EA3A3E4877DQ35534349-5DA74EF0-9552-4271-868B-0FE806DCD8A0Q35550573-39450450-D82C-48F6-B653-810D716E2A4CQ35772768-C9015AB1-47F5-4E05-8990-66A132641079Q35832237-624F4CF7-C83B-4F4F-AE34-40A86ECE5847Q35879907-CF6F4A50-3AA5-416C-8731-C8E7A56AC47BQ35896269-EB297194-F23D-45AF-BAD5-0017B6094998Q36880844-2A784120-869C-48F7-B014-B43D311BD21AQ37082894-EC1426F7-D656-414D-A195-25EDFB94C106Q37100087-BFD83FD8-BBEB-4FDE-A4E3-E41681BE4196Q37289187-727FEA33-6248-43C2-8158-84BDDDD53CB1Q37316881-6D7D84D9-1E9E-41AD-80D0-29CA7D896FAFQ37723730-DF0780A6-1D7B-47C1-8335-632D5D661CBAQ37970745-72D4D1F2-50B0-4472-8E0E-08AD73050CB1Q37977179-5B3C87E2-43D2-4D34-AE6A-8FDCD78E0C3AQ37980726-CBA24266-404A-4893-9D82-1DF88F46FA91Q38199643-6485ABFB-59AA-4EFA-B7AB-C5115FB17564Q38289992-749347B8-18CB-475C-B064-91122FCF7FB3Q38548814-95723CC5-44A6-4796-95BF-10FF886764BCQ38660465-C7F6DCE6-2182-4389-B029-2224A479B764Q38833684-B7D0189D-A62A-4CA9-B7DE-6A2145C3C4B1Q38868188-D6DF4E76-3AE7-4DEA-BFA0-061E5280288FQ39084992-47754035-E0A6-4C45-9F76-8F39104C1CAFQ39241435-77AD3675-2770-431A-8EEF-D5A0BC176AC8Q39314490-DC0C6E1E-208A-4577-87BF-AC348766DD6DQ39434337-9FAD9EEF-D535-4072-90E4-AE02B4BFAF10Q39446317-066C5BFD-B5A3-41F5-995B-F2A8802121A6
P2860
Oncogenic mutant forms of EGFR: lessons in signal transduction and targets for cancer therapy.
description
2010 nî lūn-bûn
@nan
2010 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Oncogenic mutant forms of EGFR ...... nd targets for cancer therapy.
@ast
Oncogenic mutant forms of EGFR ...... nd targets for cancer therapy.
@en
type
label
Oncogenic mutant forms of EGFR ...... nd targets for cancer therapy.
@ast
Oncogenic mutant forms of EGFR ...... nd targets for cancer therapy.
@en
prefLabel
Oncogenic mutant forms of EGFR ...... nd targets for cancer therapy.
@ast
Oncogenic mutant forms of EGFR ...... nd targets for cancer therapy.
@en
P2093
P2860
P1433
P1476
Oncogenic mutant forms of EGFR ...... nd targets for cancer therapy.
@en
P2093
Wolfgang J Köstler
Yosef Yarden
P2860
P304
P356
10.1016/J.FEBSLET.2010.04.019
P407
P577
2010-04-11T00:00:00Z